39
Participants
Start Date
March 31, 2024
Primary Completion Date
April 20, 2026
Study Completion Date
August 31, 2027
Zanubrutinib combined with Obinutuzumab
Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
RECRUITING
Bing Xu, Xiamen
Shaanxi Provincial Cancer Hospital
OTHER
The First Hospital of Jilin University
OTHER
Fujian Cancer Hospital
OTHER_GOV
Jiangxi Provincial Cancer Hospital
OTHER
The Second Affiliated Hospital of Dalian Medical University
OTHER
Sun Yat-sen University
OTHER
Huazhong University of Science and Technology
OTHER
The First Affiliated Hospital of Xiamen University
OTHER